

Ref No : ⁷⁰⁰⁶ /STCL/ST/2023-24Date: 22nd December, 2023

To

BSE Limited Phiroze Jeejebhoy Towers, Dalal Street, Mumbai – 400 001	National Stock Exchange of India Limited Exchange Plaza, Plot No. C/1, G Block, Bandra Kurla Complex, Bandra (E), Mumbai 400 051	Orchid Pharma Limited Orchid Towers, 313, Valluvar Kottam High Rd, Nungambakkam, Chennai, TN 600034 Plot No 121-128, 128a-133, 138-151, 159-164 SIDCO Industrial Estate, Alathur, Chengalpattu, Alathur Industrial Estate, Kanchipuram, Chengalpattu, Tamil Nadu, India, 603110
--	---	---

Dear Sir,

Sub: Disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011- Orchid Pharma Limited

Please find attached the Disclosures which are required to be made under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 in respect of sale of the shares of Orchid Pharma Limited pledged in our favour in our capacity as Security Trustee for the benefits of the Lenders.

You are requested to take note of the same on your records.

Yours faithfully,
For SBICAP Trustee Company Limited


Authorized Signatory



Disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Name of the Target Company (TC)	Orchid Pharma Limited		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	SBICAP Trustee Company Limited (“STCL”)		
Whether the acquirer belongs to Promoter/Promoter group	NO		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	BSE & NSE		
Details of the acquisition / disposal as follows	Number	% w.r.t. total share/voting capital wherever applicable(*)	% w.r.t. total diluted share/voting capital of the TC (**)
Before the acquisition/disposal under consideration, holding of :			
a) Shares carrying voting rights	a) 85,167	a) 0.17	a) 0.17
b) Shares in the nature of encumbrance (pledge/lien/ non-disposal undertaking/ others)	b) 15,846	b) 0.03	b) 0.03
c) Voting rights (VR) otherwise than by shares			
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the T C (specify holding in each category)			
e) Total (a+b+c+d)	e) 1,01,013	e) 0.20	e) 0.20
Details of acquisition/sale/release			
a) Shares carrying voting rights acquired /sold	a) 69,782	a) 0.14	a) 0.14
b) VRs acquired /sold otherwise than by shares			
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired /sold			
d) Shares encumbered/invoked/released by the acquirer			
e) Total (a+b+c+/-d)	e) 69,782	e) 0.14	e) 0.14



After the acquisition/sale/release, holding of: a) Shares carrying voting rights b) Shares encumbered with the seller c) VRs otherwise than by shares d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition e) Total (a+b+c+d)	a) 15,385 b) 15,846 e) 31,231	a) 0.03 b) 0.03 e) 0.06	a) 0.03 b) 0.03 e) 0.06
Mode of acquisition/sale (e.g. open market/off-market / public issue/rights issue/preferential allotment/inter-se transfer etc)	# Sale in Open Market		
Date of acquisition/sale of shares/VR or date of receipt of intimation of allotment of shares/release whichever is applicable	22.12.2023		
Equity Share capital/total voting capital of the TC before the said acquisition/sale/release	5,07,19,105 equity shares of Rs.10/- each aggregating Rs. 50,71,91,050/- (as per BSE shareholding pattern as on dated 30-09-2023)		
Equity Share capital/total voting capital of the TC after the said acquisition/sale/release	5,07,19,105 equity shares of Rs.10/- each aggregating Rs. 50,71,91,050/- (as per BSE shareholding pattern as on dated 30-09-2023)		
Total diluted Share/voting capital of the TC after the said acquisition/sale/release	5,07,19,105 equity shares of Rs.10/- each aggregating Rs. 50,71,91,050/- (as per BSE shareholding pattern as on dated 30-09-2023)		

(*) Total share capital/ voting capital to be taken as per the latest filing (September 30, 2023) done by the company to the Stock Exchange under Clause 35 of the listing Agreement.

(**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

(***) STCL acts as a Security Trustee, Debenture Trustee, Share Pledge Trustee etc. It is not the business of STCL to lend the money to any entity/company/individual or borrow the money or to provide the security to any lender / borrower. STCL only holds the security created in its favour for the benefit of the debenture holders/lender as required under the transaction documents. Further, in case the default in repayment of loans/debentures is made by the borrower/Issuer Company, STCL will be required to enforce the security created in its favour, as per the instructions/direction of the lenders/debenture holders as required under the transaction documents.



(#) 1,01,013 (0.20%) equity share of Orchid Pharma Limited ('Company') were pledged with SBICAP Trustee Company Limited. On 19.12.2023, the pledge was invoked and 85,167 (i.e.0.17%) Equity Shares out of 1,01,013 total pledged equity shares were transferred to our Demat Account. The necessary disclosure was made under regulation 29(2) for invocation of abovementioned equity shares of the company to stock exchanges on 20.12.2023. Now as disclosed above 69,782 equity shares of the company were sold in open market and hence this disclosure is being made as under SEBI (Substantial Acquisition of Shares and Takeover) Regulation, 2011.

Place : Mumbai
Date : 22.12.2023

Signature of the acquirer/seller/Authorised Signatory
For SBICAP Trustee Company Limited


Authorized Signatory 